{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:08:42Z","timestamp":1788570522403,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Renal dysfunction is common in patients with cancer and affects their pharmacokinetics, thereby altering treatment efficacy and safety. This review outlines the principles of dose adjustment based on renal function and highlights specific issues in patients undergoing dialysis or with proteinuria. In patients undergoing dialysis, dose adjustment can be rational if drug properties such as molecular weight and protein binding are considered. Metabolites of some drugs, such as fluorouracil (5-FU), may accumulate in patients with impaired renal function, thereby increasing the risk of toxicity. For oxaliplatin, increased platinum exposure in patients undergoing dialysis does not necessarily increase toxicity, possibly because reactive platinum species are eliminated independent of renal function. Proteinuria can lead to reduced drug exposure to monoclonal antibodies owing to abnormal urinary excretion. The early detection and management of drug-induced kidney injuries are essential. These strategies include identifying risk factors, adjusting doses, and implementing monitoring systems. Protocol-based approaches, such as pharmacist-led monitoring, can improve cancer pharmacotherapy. Automated systems and AI-based models have also been explored for risk prediction. Future studies should focus on deepening our understanding of pharmacokinetics in patients with advanced chronic kidney disease (CKD) or those on dialysis. Multidisciplinary collaboration in onco-nephrology is important to improve cancer care in this growing population.  <\/jats:p>","DOI":"10.1007\/s10147-025-02832-z","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T18:41:49Z","timestamp":1752777709000},"page":"1700-1706","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Onco-nephrology in clinical practice: pharmacokinetics, monitoring, and treatment strategies for patients with cancer and impaired renal function"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1285-122X","authenticated-orcid":false,"given":"Shunsaku","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Ikuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"issue":"6","key":"2832_CR1","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/cncr.22904","volume":"110","author":"V Launay-Vacher","year":"2007","unstructured":"Launay-Vacher V, Oudard S, Janus N et al (2007) Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 110(6):1376\u20131384. https:\/\/doi.org\/10.1002\/cncr.22904","journal-title":"Cancer"},{"issue":"6","key":"2832_CR2","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.eururo.2015.04.043","volume":"68","author":"BR Lane","year":"2015","unstructured":"Lane BR, Demirjian S, Derweesh IH et al (2015) Survival and functional stability in chronic kidney disease due to surgical removal of nephrons: importance of the new baseline glomerular filtration rate. Eur Urol 68(6):996\u20131003. https:\/\/doi.org\/10.1016\/j.eururo.2015.04.043","journal-title":"Eur Urol"},{"issue":"1","key":"2832_CR3","first-page":"38","volume":"53","author":"Y Nakamura","year":"2011","unstructured":"Nakamura Y, Tsuchiya K, Nitta K et al (2011) Prevalence of anemia and chronic kidney disease in cancer patients: clinical significance for 1-year mortality. Nihon Jinzo Gakkai Shi 53(1):38\u201345","journal-title":"Nihon Jinzo Gakkai Shi"},{"issue":"4","key":"2832_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ejim.2011.05.005","volume":"22","author":"CF Christiansen","year":"2011","unstructured":"Christiansen CF, Johansen MB, Langeberg WJ et al (2011) Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur J Intern Med 22(4):399\u2013406. https:\/\/doi.org\/10.1016\/j.ejim.2011.05.005","journal-title":"Eur J Intern Med"},{"issue":"3","key":"2832_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2215\/CJN.03530412","volume":"8","author":"AK Salahudeen","year":"2013","unstructured":"Salahudeen AK, Doshi SM, Pawar T et al (2013) Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin J Am Soc Nephrol 8(3):347\u2013354. https:\/\/doi.org\/10.2215\/CJN.03530412","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"2832_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1053\/j.ackd.2021.08.001","volume":"28","author":"S Gupta","year":"2021","unstructured":"Gupta S, Portales-Castillo I, Daher A et al (2021) Conventional chemotherapy nephrotoxicity. Adv Chronic Kidney Dis 28(5):402-414.e401. https:\/\/doi.org\/10.1053\/j.ackd.2021.08.001","journal-title":"Adv Chronic Kidney Dis"},{"issue":"12","key":"2832_CR7","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","volume":"14","author":"H Seethapathy","year":"2019","unstructured":"Seethapathy H, Zhao S, Chute DF et al (2019) The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol 14(12):1692\u20131700. https:\/\/doi.org\/10.2215\/CJN.00990119","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2832_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","volume":"31","author":"FB Cortazar","year":"2020","unstructured":"Cortazar FB, Kibbelaar ZA, Glezerman IG et al (2020) Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol 31(2):435\u2013446. https:\/\/doi.org\/10.1681\/ASN.2019070676","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2832_CR9","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.34067\/KID.0000000000000528","volume":"5","author":"C Yamawaki","year":"2024","unstructured":"Yamawaki C, Nakagawa S, Ikuta K et al (2024) Association between proton pump inhibitors, immune checkpoint inhibitors, and acute kidney injury: a nested case-control study. Kidney360 5(9):1262\u20131269. https:\/\/doi.org\/10.34067\/KID.0000000000000528","journal-title":"Kidney360"},{"issue":"3","key":"2832_CR10","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1152\/physrev.2000.80.3.1107","volume":"80","author":"M Wyss","year":"2000","unstructured":"Wyss M, Kaddurah-Daouk R (2000) Creatine and creatinine metabolism. Physiol Rev 80(3):1107\u20131213. https:\/\/doi.org\/10.1152\/physrev.2000.80.3.1107","journal-title":"Physiol Rev"},{"issue":"11","key":"2832_CR11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.7326\/0003-4819-156-11-201203200-00391","volume":"156","author":"A Earley","year":"2012","unstructured":"Earley A, Miskulin D, Lamb EJ et al (2012) Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 156(11):785\u2013795. https:\/\/doi.org\/10.7326\/0003-4819-156-11-201203200-00391","journal-title":"Ann Intern Med"},{"issue":"6","key":"2832_CR12","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M et al (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53(6):982\u2013992. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"2832_CR13","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s10147-023-02372-4","volume":"28","author":"S Muto","year":"2023","unstructured":"Muto S, Matsubara T, Inoue T et al (2023) Chapter 1: evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. Int J Clin Oncol 28(10):1259\u20131297. https:\/\/doi.org\/10.1007\/s10147-023-02372-4","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"2832_CR14","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1007\/s10147-023-02377-z","volume":"28","author":"H Nishiyama","year":"2023","unstructured":"Nishiyama H, Inoue T, Koizumi Y et al (2023) Chapter 2: indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. Int J Clin Oncol 28(10):1298\u20131314. https:\/\/doi.org\/10.1007\/s10147-023-02377-z","journal-title":"Int J Clin Oncol"},{"key":"2832_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103161","volume":"82","author":"G Sandhu","year":"2025","unstructured":"Sandhu G, Adattini J, Armstrong Gordon E et al (2025) Integrating international consensus guidelines for anticancer drug dosing in kidney dysfunction (ADDIKD) into everyday practice. EClinicalMedicine 82:103161. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103161","journal-title":"EClinicalMedicine"},{"issue":"2","key":"2832_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000301","volume":"3","author":"T Funakoshi","year":"2018","unstructured":"Funakoshi T, Horimatsu T, Nakamura M et al (2018) Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan. ESMO Open 3(2):e000301. https:\/\/doi.org\/10.1136\/esmoopen-2017-000301","journal-title":"ESMO Open"},{"issue":"4","key":"2832_CR17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/0002-9343(77)90400-4","volume":"62","author":"JF Maher","year":"1977","unstructured":"Maher JF (1977) Principles of dialysis and dialysis of drugs. Am J Med 62(4):475\u2013481. https:\/\/doi.org\/10.1016\/0002-9343(77)90400-4","journal-title":"Am J Med"},{"issue":"5","key":"2832_CR18","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1007\/s11030-021-10348-7","volume":"26","author":"K Nishikiori","year":"2022","unstructured":"Nishikiori K, Tanaka K, Uesawa Y (2022) Construction of a prediction model for drug removal rate in hemodialysis based on chemical structures. Mol Divers 26(5):2647\u20132657. https:\/\/doi.org\/10.1007\/s11030-021-10348-7","journal-title":"Mol Divers"},{"issue":"9","key":"2832_CR19","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/CAD.0000000000000911","volume":"31","author":"NGL Jager","year":"2020","unstructured":"Jager NGL, Sari V, Westermann AM et al (2020) Full-dose cisplatin chemotherapy combined with hemodialysis in a patient with impaired renal function and a mediastinal germ cell tumor. Anticancer Drugs 31(9):983\u2013987. https:\/\/doi.org\/10.1097\/CAD.0000000000000911","journal-title":"Anticancer Drugs"},{"issue":"3","key":"2832_CR20","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00280-011-1802-x","volume":"69","author":"M Hiraike","year":"2012","unstructured":"Hiraike M, Hiraki Y, Misumi N et al (2012) Pharmacokinetics of carboplatin in a hemodialysis patient with small-cell lung cancer. Cancer Chemother Pharmacol 69(3):845\u2013848. https:\/\/doi.org\/10.1007\/s00280-011-1802-x","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"2832_CR21","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","volume":"40","author":"AB van Kuilenburg","year":"2004","unstructured":"van Kuilenburg AB (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40(7):939\u2013950. https:\/\/doi.org\/10.1016\/j.ejca.2003.12.004","journal-title":"Eur J Cancer"},{"issue":"3","key":"2832_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00280-017-3249-1","volume":"79","author":"Y Nishikawa","year":"2017","unstructured":"Nishikawa Y, Funakoshi T, Horimatsu T et al (2017) Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. Cancer Chemother Pharmacol 79(3):629\u2013633. https:\/\/doi.org\/10.1007\/s00280-017-3249-1","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"2832_CR23","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00280-020-04158-1","volume":"86","author":"Y Ozaki","year":"2020","unstructured":"Ozaki Y, Imamaki H, Ikeda A et al (2020) Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses. Cancer Chemother Pharmacol 86(5):693\u2013699. https:\/\/doi.org\/10.1007\/s00280-020-04158-1","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2832_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00280-023-04577-w","volume":"93","author":"H Imamaki","year":"2024","unstructured":"Imamaki H, Oura M, Oguro F et al (2024) Removal rate of 5-fluorouracil and its metabolites in patients on hemodialysis: a report of two cases of colorectal cancer patients with end-stage renal failure. Cancer Chemother Pharmacol 93(2):161\u2013167. https:\/\/doi.org\/10.1007\/s00280-023-04577-w","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2832_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s002800050024","volume":"45","author":"C Massari","year":"2000","unstructured":"Massari C, Brienza S, Rotarski M et al (2000) Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol 45(2):157\u2013164. https:\/\/doi.org\/10.1007\/s002800050024","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"2832_CR26","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0090-9556(24)15087-8","volume":"28","author":"P Allain","year":"2000","unstructured":"Allain P, Heudi O, Cailleux A et al (2000) Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab Dispos 28(11):1379\u20131384","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"2832_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1248\/bpb.b22-00578","volume":"46","author":"S Nakagawa","year":"2023","unstructured":"Nakagawa S, Shimazaki A, Funakoshi T et al (2023) Effect of severe renal dysfunction on the plasma levels of DNA-reactive platinum after oxaliplatin administration. Biol Pharm Bull 46(2):194\u2013200. https:\/\/doi.org\/10.1248\/bpb.b22-00578","journal-title":"Biol Pharm Bull"},{"issue":"4","key":"2832_CR28","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/jcpt.12661","volume":"43","author":"IRF van Berlo-van de Laar","year":"2018","unstructured":"van Berlo-van de Laar IRF, Brummelhuis WJ, Imholz ALT et al (2018) Dosing oxaliplatin in a haemodialysis patient with metastatic rectum cancer monitored by free platinum concentrations. J Clin Pharm Ther 43(4):574\u2013577. https:\/\/doi.org\/10.1111\/jcpt.12661","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"2832_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00280-011-1633-9","volume":"68","author":"T Horimatsu","year":"2011","unstructured":"Horimatsu T, Miyamoto S, Morita S et al (2011) Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. Cancer Chemother Pharmacol 68(1):263\u2013266. https:\/\/doi.org\/10.1007\/s00280-011-1633-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"2832_CR30","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J et al (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358(11):1129\u20131136. https:\/\/doi.org\/10.1056\/NEJMoa0707330","journal-title":"N Engl J Med"},{"issue":"4","key":"2832_CR31","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00280-024-04659-3","volume":"94","author":"T Masuda","year":"2024","unstructured":"Masuda T, Funakoshi T, Horimatsu T et al (2024) Low serum concentrations of bevacizumab and nivolumab owing to excessive urinary loss in patients with proteinuria: a case series. Cancer Chemother Pharmacol 94(4):615\u2013622. https:\/\/doi.org\/10.1007\/s00280-024-04659-3","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2832_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s00280-025-04769-6","volume":"95","author":"T Masuda","year":"2025","unstructured":"Masuda T, Funakoshi T, Horimatsu T et al (2025) Population pharmacokinetic analysis of bevacizumab in Japanese cancer patients with proteinuria: a prospective cohort study. Cancer Chemother Pharmacol 95(1):46. https:\/\/doi.org\/10.1007\/s00280-025-04769-6","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"2832_CR33","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s10147-023-02382-2","volume":"28","author":"Y Ando","year":"2023","unstructured":"Ando Y, Nishiyama H, Shimodaira H et al (2023) Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. Int J Clin Oncol 28(10):1315\u20131332. https:\/\/doi.org\/10.1007\/s10147-023-02382-2","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"2832_CR34","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/jcpt.13207","volume":"45","author":"H Ikesue","year":"2020","unstructured":"Ikesue H, Kusuda K, Satsuma Y et al (2020) Evaluation of the usefulness of protocol-based pharmacist-facilitated laboratory monitoring to ensure the safety of immune checkpoint inhibitors in patients with lung cancer. J Clin Pharm Ther 45(6):1288\u20131294. https:\/\/doi.org\/10.1111\/jcpt.13207","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"2832_CR35","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1681\/ASN.2017070765","volume":"29","author":"M Al-Jaghbeer","year":"2018","unstructured":"Al-Jaghbeer M, Dealmeida D, Bilderback A et al (2018) Clinical decision support for in-hospital AKI. J Am Soc Nephrol 29(2):654\u2013660. https:\/\/doi.org\/10.1681\/ASN.2017070765","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2832_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298673","volume":"19","author":"M Sakuragi","year":"2024","unstructured":"Sakuragi M, Uchino E, Sato N et al (2024) Interpretable machine learning-based individual analysis of acute kidney injury in immune checkpoint inhibitor therapy. PLoS ONE 19(3):e0298673. https:\/\/doi.org\/10.1371\/journal.pone.0298673","journal-title":"PLoS ONE"},{"issue":"7","key":"2832_CR37","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41581-022-00562-3","volume":"18","author":"TJ Loftus","year":"2022","unstructured":"Loftus TJ, Shickel B, Ozrazgat-Baslanti T et al (2022) Artificial intelligence-enabled decision support in nephrology. Nat Rev Nephrol 18(7):452\u2013465. https:\/\/doi.org\/10.1038\/s41581-022-00562-3","journal-title":"Nat Rev Nephrol"},{"key":"2832_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1146\/annurev.pharmtox.48.113006.094615","volume":"48","author":"VS Vaidya","year":"2008","unstructured":"Vaidya VS, Ferguson MA, Bonventre JV (2008) Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 48:463\u2013493. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094615","journal-title":"Annu Rev Pharmacol Toxicol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02832-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02832-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02832-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:36:52Z","timestamp":1757252212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02832-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2832"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02832-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}